These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 8627275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Double-blind, placebo-controlled, multicenter trial of selegiline augmentation of antipsychotic medication to treat negative symptoms in outpatients with schizophrenia.
    Bodkin JA, Siris SG, Bermanzohn PC, Hennen J, Cole JO.
    Am J Psychiatry; 2005 Feb; 162(2):388-90. PubMed ID: 15677608
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: findings from the CLAMORS study.
    Bobes J, Arango C, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group.
    J Clin Psychiatry; 2010 Mar; 71(3):280-6. PubMed ID: 19895779
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
    Amiri A, Noorbala AA, Nejatisafa AA, Ghoreishi A, Derakhshan MK, Khodaie-Ardakani MR, Hajiazim M, Raznahan M, Akhondzadeh S.
    Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
    [Abstract] [Full Text] [Related]

  • 8. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
    Strzelecki D, Kropiwnicki P, Rabe-Jabłońska J.
    Psychiatr Pol; 2013 Mar; 47(4):609-20. PubMed ID: 24946468
    [Abstract] [Full Text] [Related]

  • 9. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
    Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME.
    Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X, Savage R, Borisov A, Rosenberg J, Woolwine B, Tucker M, May R, Feldman J, Nemeroff CB, Miller AH.
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR, Mahmoud R.
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [Abstract] [Full Text] [Related]

  • 14. Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial.
    Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, Mohamed S, Jeste DV.
    J Clin Psychiatry; 2009 Apr; 70(4):562-71. PubMed ID: 19192468
    [Abstract] [Full Text] [Related]

  • 15. Vitamin B6 as add-on treatment in chronic schizophrenic and schizoaffective patients: a double-blind, placebo-controlled study.
    Lerner V, Miodownik C, Kaptsan A, Cohen H, Loewenthal U, Kotler M.
    J Clin Psychiatry; 2002 Jan; 63(1):54-8. PubMed ID: 11838627
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
    Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA.
    Biol Psychiatry; 1993 May 15; 33(10):700-6. PubMed ID: 8102552
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.